

Haematologica  
HAEMATOL/2020/247346  
Version 3

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD  
acute myeloid leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Benjamin Powell,  
Chao Zhang, Yan Ma, Maiko Narahara, Hiroyuki Sumi, Daniela  
Hernandez, Trivikram Rajkhowa, Gideon Bollag, and Mark Levis

Disclosures: Lauren Lee, Daniela Hernandez, and Trivikram Rajkhowa declare no conflict of interest. Mark Levis is a consultant to Daiichi-Sankyo, Astellas, Novartis, FujiFilm, Amgen, and Agios, and receives research funding from Astellas, FujiFilm, and Novartis. Paul Severson, Benjamin Powell, Chao Zhang, Yan Ma, and Gideon Bollag are employees of Plexikon, whose product, PLX51107, is a subject of this research. Yoshiyuki Hizukuri, Maiko Narahara, and Hiroyuki Sumi are employees of Daiichi-Sankyo, whose product, quizartinib, is a subject of this research.

Contributions: Lee- Performed experiments, analyzed data, wrote the manuscript Hizukuri- employed by Daiichi-Sankyo Ltd. Severson- Performed experiments, analyzed data, edited the manuscript Powell- Performed experiments, analyzed data, edited the manuscript. Zhang- Performed experiments, analyzed data, edited the manuscript Ma- Performed experiments, analyzed data, edited the manuscript Narahara- Performed experiments, analyzed data, edited the manuscript Sumi- Performed experiments, analyzed data, edited the manuscript Severson- Performed experiments, analyzed data, edited the manuscript Hernandez- Performed experiments, analyzed data, edited the manuscript Rajkhowa- Performed experiments, analyzed data, edited the manuscript Bollag- Designed the study, analyzed data, edited the manuscript Levis- Designed the study, analyzed data, wrote the manuscript